Immunovia announces updated financial calendar for financial year 2023

                         

LUND (SWEDEN) - Immunovia, a diagnostic company with the vision to revolutionize blood-based diagnostics and survival rates for patients with cancer, announces its financial calendar for 2023 and 2024.

 

February 23, 2023	Year-end report 2022
April 25, 2023	Q1 2023
August 23, 2023	Q2 2023
November 9, 2023	Q3 2023
February 21, 2024	Year-end report 2023

 

The Annual General Meeting will be held on April 26, 2023.

 

For more information, please contact:
Karin Almqvist Liwendahl
CFO
[e-mail]
[phone]

 

About Immunovia 
Immunovia AB is a diagnostic company with the vision to revolutionize blood-based diagnostics and increase survival rates for patients with cancer.

Our first product, IMMray^(TM) PanCan-d is the only blood test currently available for early detection of pancreatic cancer. The test has unmatched clinical performance. Commercialization of IMMray^(TM) PanCan-d started in August 2021 in the USA and IMMray^(TM) PanCan-d is offered as a laboratory developed test (LDT) exclusively through Immunovia, Inc. For more information see: www.immunoviainc.com.

Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups globally to make this test available to all high-risk pancreatic cancer groups. 

The USA, the first market in which IMMray^(TM) PanCan-d is commercially available, is the world's largest market for the detection of pancreatic cancer with an estimated value of more than USD 4 billion annually.

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com. 

 

                                                                           ###

https://news.cision.com/immunovia-ab/r/immunovia-announces-updated-financial-calendar-for-financial-year-2023,c3700247

https://mb.cision.com/Main/13121/3700247/1792232.pdf

(c) 2023 Cision. All rights reserved., source Press Releases - English